Akeso Biopharma developed novel Ivonescimab (PD-1/VEGF bispecific antibody in combination with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients.
Novel Ivonescimab is applicable for patients who have failed to respond to prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.
Ivonescimab is the first-in-class PD-1/VEGF bi-specific antibody blocking PD-1 binding toPD-L1 and PD-L2 and it also blocks VEGF binding to VEGF receptors. When PD-1 antibody combined with VEGF blocking agents have shown efficient results in different tumors such as renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma.
Ivonescimab, as a single agent can block these two VEGF and PD-1 antibodies and enhance the antitumor activity, compared to combination therapy.
To treat EGFR-mutatedlocally advanced or metastatic NSCLC patients, AK112 is combined with chemotherapy, failed to respond to EGFR-TKI treatment, having completed Phase III clinical trials patient enrollment.
PD-1/L1 monoclonal antibody in combination with platinum-based chemotherapy is the first-line therapy for patients with advanced NSCLC.
AK112 is the only drug candidate approved for NSCLC patients with PD-(L)1 resistant lung cancer treatment in China.
China National Medical Products Administration (NMPA) grants Breakthrough Therapy Designation (BTD) for Ivonescimab (PD-1/VEGFbispecific antibody for Non-Small-Cell Lung Carcinoma (NSCLC).
